Jump to start of content

Complete requirements by 12/31/19 to avoid a change in certification status Expand/Collapse the ABIM alert.

Sign in to your Physician Portal to view any remaining requirements for the year. Not completing these requirements by 12/31/19 could result in a change to your certification status.

Breadcrumb trail:

Pulmonary Disease Board

Expand All | Collapse All

Serpil C. Erzurum, MD, Chair

Serpil C. Erzurum, MDDr. Erzurum is the Alfred Lerner Chair of the Department of Pathobiology in the Lerner Research Institute, and the Program Director of the Cleveland Clinic Clinical Research Unit of the Case Clinical Translational Science Center. In these roles, she led development of translational multidisciplinary research programs to investigate human diseases. Since 1993, she has practiced as an American Board of Internal Medicine (ABIM) Board Certified pulmonologist at the Cleveland Clinic. She also holds certifications in internal medicine and critical care medicine.

Prior to the Cleveland Clinic, Dr. Erzurum practiced at the University of Pittsburgh Medical Center, in the Indian Health Service in South Dakota, and as a senior staff fellow in the pulmonary branch of the National Heart Lung and Blood Institute (NHLBI). Over the past 25 years, her National Institutes of Health (NIH)-funded studies of asthma and pulmonary vascular diseases have uncovered mechanisms and led to new therapeutic concepts.

She is a member of the Board of External Experts and Board of Scientific Counselors for NHLBI, and a Councilor of the Association of American Physicians. Dr. Erzurum chairs the research committee of the Scientific Leadership Council of the Pulmonary Hypertension Association and has been a senior fellow of the American Asthma Foundation. She is deputy editor of the American Journal of Respiratory and Critical Care Medicine since 2009. She serves on the American Board of Internal Medicine (ABIM) Council, is Chair of the ABIM Pulmonary Disease Board and is a former member of the ABIM Pulmonary Disease Board Exam Committee.

Dr. Erzurum received her medical degree in 1983 from Northeastern Ohio Universities College of Medicine. Following medicine residency at Baylor College of Medicine, she trained in pulmonary and critical care at the University of Colorado and National Jewish Center.

As of January 2017, Dr. Erzurum reported no external relationships.

Kevin M. Chan, MD

Kevin M. Chan, MDDr. Chan, who is board certified in Internal Medicine, Pulmonary Disease and Critical Care Medicine, is Fellowship Program Director for the Division of Pulmonary and Critical Care Medicine and Medical Director of Lung Transplantation at the University of Michigan. His academic career has centered on house officer education, end-stage lung disease and the infectious complications of lung transplantation.

Currently, Dr. Chan serves as the American College of Chest Physician's (ACCP) representative to the American Board of Internal Medicine (ABIM) Liaison Committee on Certification and Recertification. He is the Maintenance of Certification (MOC) Workforce Chair for the ACCP and the Thoracic Committee Vice-Chair for the United Network for Organ Sharing (UNOS). Dr. Chan is a member of the ABIM Pulmonary Disease Board. He has served as Scientific Program Chair (2011) for the ACCP and as Chair of the National Lung Review Board and Region 10 representative for UNOS.

Dr. Chan earned his medical degree at Wayne State University in Detroit, Michigan. He did his residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago and completed his pulmonary and critical care medicine fellowship training at the University of California Los Angeles Center for the Health Sciences.

As of January 2017, Dr. Chan reported the following external relationships:

Clinical research, with funding for clinical trial expenses and clinical research staff, paid directly to the University of Michigan Health Systems from the following company:

  • Gilead, to support the evaluation of an oral medication to treat respiratory syncytial virus infection in lung transplant recipients.

Dr. Chan serves in significant roles with the following healthcare-related organizations, receiving reimbursement or compensation as listed:

  • American College of Chest Physicians, serving as the MOC Workforce Chair and Vice Chair of the Membership Committee, receiving reimbursement for travel expenses.
  • Minority Organ and Tissue Transplant Education Program (MOTTEP) Michigan, serving on the Board of Directors, without compensation.
  • United Network for Organ Sharing, serving as Vice Chair, Thoracic Committee, receiving reimbursement for travel expenses.

Funding for clinical trial expenses and clinical research staff, paid directly to the University of Michigan Health Systems from the following company:

  • Washington University, to support the evaluation of extracorporeal photopheresis for the treatment of obliterative bronchiolitis in lung transplant recipients.

John H. Hansen-Faschen, MD

John H. Hansen-Faschen, MDDr. Hansen-Flaschen is the Paul F. Harron Family Professor of Medicine at the University of Pennsylvania. He co-directs the Paul Harron Lung Center, which he founded at Penn, and he serves as the Founding Editor-in-Chief of the Annals of the American Thoracic Society. Previously, Dr. Hansen-Flaschen served for 25 years as the Chief of the Pulmonary, Allergy and Critical Care Division of the Department of Medicine at Penn. He built the full-time clinical and research faculty of the division to 60 members. First as the Pulmonary Fellowship Training Program Director and then as Division Chief, he also oversaw the training of more than 180 pulmonary and critical care fellows between 1982 and 2014.

Dr. Hansen-Flaschen is board certified in both Internal Medicine and Pulmonary Disease. In addition to his administrative and editorial responsibilities, he practices consultative pulmonary medicine special focus on diagnostic dilemmas and second opinions. He also leads the multidisciplinary Nontuberculous Mycobacteria Lung Infection Clinic at Penn.

His scholarly interests focus on shared medical decision making near the end of life and on humanizing the experience of patients and family members in intensive care units. Dr. Hansen-Flaschen has published more than 90 articles and textbook chapters and has edited three books. He lectures and teaches nationally and internationally on management of advanced lung diseases near the end of life and related topics. He is a member of the American Board of Internal Medicine (ABIM) Pulmonary Disease Board and was previously a member of the ABIM Pulmonary Disease Board Exam Committee.

Dr. Hansen-Flaschen completed his bachelor's degree in chemistry with honors at Brown University and received his medical degree from New York University. He served as a resident and chief resident in medicine and then as a fellow in pulmonary and critical care medicine at the Hospital of the University of Pennsylvania.

As of January 2017, Dr. Hansen-Faschen reported the following external relationships:

Work as an author or editor for following companies, with compensation as listed:

  • UpToDate, receiving compensation for authorship.
  • American Thoracic Society, receiving compensation as Editor-in-Chief of the Annals of the American Thoracic Society, paid to the University of Pennsylvania.

Susan Murin, MD

Dr. Murin received her undergraduate degree from Rutgers University and her medical degree at New York University. She completed her residency in Internal Medicine at NYU-Bellevue and fellowship in Pulmonary and Critical Care Medicine at Yale University. She subsequently received an MSc in Clinical Epidemiology from the Harvard School of Public Health and an MBA from the UC Davis Graduate School of Management.

She is currently Vice-Chair of Internal Medicine, Interim Associate Dean for Clinical Affairs and Co-Director of Ambulatory Operations at UC Davis Health System. Former roles at UC Davis include Program Director for the Pulmonary and Critical Care fellowship, Chief of the Division of Pulmonary, Critical Care and Sleep Medicine, and Chief of the Medical Staff. Her past national service has included membership on the ACGME's Internal Medicine RRC, Chair of the Pulmonary Medicine test-writing committee for the ABIM, and Chair of the Association of Pulmonary and Critical Care Medicine Program Directors. Dr. Murin currently serves as a member of the Internal Medicine Pulmonary Disease Board. She is board certified in Internal Medicine, Pulmonary Medicine, and Critical Care Medicine.

Dr. Murin's research has been focused in two areas: epidemiology of venous thromboembolism and the effects of smoking on the natural history of breast cancer. She remains active in clinical care and teaching at both UC Davis and the Northern California VA. When not working she enjoys spending time with three children, Scuba diving and tennis.

As of November 2018, Dr. Murin reported the following external relationships:

Work as an author or editor for following companies, with compensation as listed:

  • StatPearls, receiving compensation as editor of Pulmonary Disease and Critical Care sections.

Kevin M. O'Neil, MD

Dr. O'Neil is board certified in Internal Medicine, Pulmonary Medicine, Critical Care and Sleep Medicine. He is in private practice and a partner at Wilmington Health, a multispecialty group in Wilmington, NC. Dr. O’Neil holds an undergraduate degree in Chemical Engineering from the University of Delaware, a Medical Degree from Jefferson Medical College in Philadelphia and a master's in healthcare administration from the University of North Carolina at Chapel Hill. He completed his residency and fellowship training at the Naval Hospital in Portsmouth, Virginia.

He served in a variety of roles while on active duty including chief medical resident, Chair, Critical Care Medicine, Pulmonary Division Chief, Pulmonary & Critical Care fellowship Program Director, Navy specialty leader for Pulmonary/CCM and GME Director for the National Naval Medical Center.

Dr. O’Neil serves as a member of the American Board of Internal Medicine Pulmonary Disease Board. He is active in clinical practice guideline development with the American College of Chest Physicians and in respiratory care education through the Commission on Accreditation for Respiratory Care (CoARC).

As of May 2019, Dr. O'Neil reported the following external relationships:

Dr. O’Neil serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American College of Chest Physicians, Chair, Guidelines Committee, Member of Programming Committee for Annual Meeting, receiving reimbursement for travel expenses.
  • Committee on Accreditation for Respiratory Care, Commissioner and Executive Committee Member, serving as Treasurer, receiving reimbursement for travel expenses.

Lynn T. Tanoue, MD

Lynn T. Tanoue, MDDr. Tanoue, who is board certified in Internal Medicine, Pulmonary Disease and Critical Care Medicine, is Professor of Medicine and Clinical Chief of the Section of Pulmonary, Critical Care, and Sleep Medicine, and Vice-Chair for Clinical Affairs in the Department of Internal Medicine at Yale School of Medicine in New Haven, Connecticut. She co­directs the Yale Thoracic Oncology Program and the Yale Screening and Nodule Program at Smilow Cancer Hospital at Yale-New Haven and is the principal investigator of the Yale Lung Cancer Biorepository. Her academic focus is in the field of thoracic oncology.

Dr. Tanoue is currently Chair of the American Board of Internal Medicine (ABIM) Pulmonary Disease Board Exam Committee and a member of the ABIM Pulmonary Disease Board. She is Chair of the American College of Chest Physicians Thoracic Oncology Network Steering Committee. She is Chair of the American Thoracic Society Thoracic Oncology Assembly. She is a former President of the National Association for Medical Direction of Respiratory Care.

Dr. Tanoue received her bachelor's degree from Harvard University and medical degree from Yale School of Medicine. She did her internal medicine residency, chief residency and a fellowship in pulmonary/critical care medicine at Yale-New Haven Hospital.

As of January 2017, Dr. Tanoue reported the following external relationships:

Work as an author or editor for the following companies, with compensation as listed:

  • UpToDate, receiving compensation for authorship.
  • Elsevier, receiving compensation as an Editor of “Year Book of Pulmonary Disease.”

Dr. Tanoue serves in significant roles with the following healthcare-related organization, receiving reimbursement or compensation as listed:

  • American Thoracic Society, Program Chair, Thoracic Oncology Assembly, without compensation.

Dr. Tanoue serves as a consultant to the Norwalk Hospital Thoracic Tumor Board, receiving honoraria.

Carol K. Yochum

Carol K. YochumMs. Yochum is retired. She had a career for over 35 years in Management and as a Financial Analyst. Ms. Yochum currently serves as a member of the American Board of Internal Medicine Pulmonary Disease Board.

After several years of shortness of breath, wheezing and of lung infections she was finally diagnosed with Alpha 1 Antitrypsin Deficiency (A1AD or AATD) a genetic disorder that may result in lung disease or liver disease. She was severely affected in her lungs and began augmentation therapy to slow down the progression of the disease. Since her lungs were very severely damaged and she was otherwise healthy it was suggested for her to have a bilateral lung transplant.

After diagnosed with Alpha 1 and of need of a lung transplant she had to move through this new reality and concentrate on learning about it and adapting to a new lifestyle. She became involved in several pulmonary and Alpha 1 online support groups, attended pulmonary rehabilitation and became an advocate in the Alpha 1 community.

In early 2015 she received her bilateral lung transplant; the first year she interacted with her transplant pulmonologists and all the clinicians nearly weekly. She found that her life as a lung transplant patient made you become mindful of everything. Throughout the past four years of her transplant life there have been many challenges as it tests the limits of human strength and courage. It also requires commitment, faith as well as mental, emotional and physical endurance.

Ms. Yochum is originally from Minnesota and has lived in Colorado for most of her life. She has a bachelors degree in Business from Regis University. She and her husband have six adult children and seven grand-children most of them living in the midwest.

As of June 2019, Ms Yochum reported no ongoing external relationships:

Corinne R. Young, NP, FCCP

Corinne R. Young, NP, FCCPMs. Young is a Nurse Practitioner (NP) who began working in pulmonary disease in California in 2005, and since 2011, she has worked in a private pulmonary practice in Colorado Springs, Colorado. Ms. Young is currently one of 10 NPs nationwide to become a Fellow of the American College of Chest Physicians.

Involvement and the representation of advanced practice providers in the pulmonary world has been one of her priorities, so that Ms. Young founded and is the President of the Association of Pulmonary Advanced Practice Providers (APAPP), a community for NPs and Physician Assistants working in pulmonary medicine. She also works closely with the American College of Chest Physicians’ CHEST programs and serves on the Interprofessional Team Network, Clinical Research Network, and on the Executive Programing Committee. Additionally, Ms. Young is a member of the American Board of Internal Medicine Pulmonary Disease Board.

Ms. Young's education started as a bachelor's-prepared registered nurse working in critical care in medical, surgical, cardiac and trauma ICUs. She then pursued her master's degree in nursing at California State University, Bakersfield Family Practice Nurse Practitioner program and became board certified in Family Practice through the American Association of Nurse Practitioners.

As of May 2018, Ms Young reported the following external relationships:

Funding for clinical trial expenses, paid to Colorado Springs Pulmonary Consultants, from the following companies:

  • AstraZeneca, for an observational chronic obstructive pulmonary disease trial.
  • GlaxoSmithKline, for a trial for treatment of chronic obstructive pulmonary disease exacerbations.